{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'If a female subject becomes pregnant during the Treatment Period, she should immediately', 'notify the Investigator, and teprotumumab dosing should be permanently discontinued.', 'Pregnancy occurring in the partner of a male subject participating in the study should be reported', 'to the Investigator and the Sponsor. Monitoring of the partner should continue until conclusion', 'of the pregnancy.', 'Pregnancies occurring up to 180 days after the last dose must also be reported to the Investigator.', 'The Investigator should report pregnancies to the Sponsor within 24 hours by submitting the', 'completed pregnancy report form by email to', 'fax, or', \"telephone within 24 hours after becoming aware that the subject/subject's female partner has\", 'become pregnant (see Appendix 17.1 for contact information). The Investigator should counsel', 'the subject and discuss the possible risks of continuing the pregnancy. If pregnancy continues,', 'monitoring should also continue to the conclusion of the pregnancy.', 'Subjects should be instructed to continue contraception for 180 days after their last dose of study', 'drug.', '9.5.4.3 Vital Signs', 'Vital signs (heart rate, blood pressure, respiratory rate, temperature) will be measured at all clinic', 'visits. Vital signs will be measured pre- and post-infusion on Day 1 and Week 3, and predose on', 'any other infusion day. In addition, if immediate infusion-associated events are noted during the', 'infusion, vital signs will be monitored every 5 minutes until stable and then every 15 minutes for', '2 additional determinations. Also, vital signs will be monitored every 15 minutes from the start', 'of the infusion through 60 minutes after infusion completion for any subsequent infusions after', 'the previous occurrence of immediate or delayed infusion-associated events.', \"Blood pressure and pulse measurements will be obtained with the subject's arm unconstrained by\", 'clothing or other material and while the subject is sitting up. When possible, the same arm will', 'be used for measurements in all study visits.', '9.5.4.4 Physical and Ophthalmic Examinations, Height, and Weight', 'A physical examination, including complete undilated ophthalmic examination, will be', 'performed at Baseline (Day 1) and thereafter at Weeks 1, 6, 12, 18, and 24 (or PW) during the', 'Treatment Period and Month 12 (or PW) of the Follow-Up Period.', 'The ophthalmic exam should include best-corrected visual acuity, pupil exam, color vision', 'assessment, Ishihara color plates (or equivalent) or related red desaturation, intraocular pressure', 'and slit lamp exam. If significant abnormalities are noted compared with previous visits,', 'including a loss of 2 lines or more of vision, development of pupil abnormalities including', 'afferent pupillary defect (APD), rise in intraocular pressure, development of corneal infiltrates or', 'other abnormalities not here specified but of concern to the ophthalmologist, further', 'investigations of visual function will be conducted according to the ophthalmologist decision.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 91 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'New findings reported from on-study ophthalmic examinations will not be reported as AEs if,', 'according to the Investigator, the abnormalities are related to TED and not related to the study', 'drug.', 'Physical exam will include assessment of presence or absence of pretibial myxedema on Day 1', 'and Week 24 (or PW) of the Treatment Period and Month 12/PW of the Follow-Up Period. If', 'present, measurements of instep and calf will be taken.', 'Weight will be measured at Baseline and every 12 weeks throughout the study (Weeks 12 and 24', 'or PW] during the Treatment Period and Months 9 and 12 [or PW] of the Follow-Up Period).', 'The dose on Day 1 may be based on the weight determined at the most recent clinic visit,', 'provided the most recent visit was within the prior 3 weeks. The doses on Week 3 through', 'Week 9 will be based on the weight determined on Day 1. The weight used in the Week 12 dose', 'calculation can be the weight determined on Day 1 or the weight obtained at Week 12. The', 'weight obtained at Week 12 can be used to adjust the dose beginning at Week 12 or Week 15', 'through Week 21, as appropriate.', '9.5.4.5 ECGs', '12-lead ECGs will be performed at Baseline, Weeks 3, 6, 12, and 24 (or PW) of the Treatment', 'Period, and Month 12 (or PW) of the Follow-Up Period. At infusion visits, the ECG will be', 'performed prior to the infusion. The results will be recorded as normal or abnormal on the eCRF', 'and all abnormal results will be evaluated as clinically (CS) or not clinically significant (NCS)', 'by the Investigator. A copy of the ECG tracing will remain with the source documents.', '9.5.4.6 Clinical Laboratory Safety Tests', 'With the exception of urine pregnancy tests, a central study laboratory will be used for all', 'protocol-specified clinical laboratory parameters. Urine pregnancy tests will be performed', 'locally (see Section 9.5.4.2 for details). Details concerning the collection of these samples are', 'presented in Table 9.4.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 92 of 118']\n\n###\n\n", "completion": "END"}